Arcellx Doses First Patient in Phase 1 study of ACLX-001 in Relapsed or Refractory Multiple Myeloma

Arcellx, Inc. ACLX announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

The Phase 1 clinical trial is currently evaluating the novel ARC-SparX program in patients with relapsed or refractory multiple myeloma

Rami Elghandour, Chairman and CEO, said, "Our ARC-SparX platform, powered by our proprietary D-Domain technology, has the potential to yield transformative therapies that can unleash the full potential of CAR-Ts to treat challenging conditions, including solid tumors. By addressing antigen heterogeneity and dose limiting toxicities, ARC-SparX could help many patients and address significant unmet clinical needs.”

The company is planning to enrol additional patients in this study.

Initial data readout from the ACLX-001 Phase 1 study is anticipated in 2023.

Arcellx closed regular trading up 14 percent at $9.69.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapFDAGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!